Hsbc Holdings PLC Increases Stock Position in West Pharmaceutical Services, Inc. (NYSE:WST)

Hsbc Holdings PLC raised its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 11.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 186,718 shares of the medical instruments supplier’s stock after acquiring an additional 19,561 shares during the period. Hsbc Holdings PLC owned 0.26% of West Pharmaceutical Services worth $61,727,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Fidelis Capital Partners LLC purchased a new position in West Pharmaceutical Services during the 1st quarter worth approximately $27,000. Crewe Advisors LLC grew its position in shares of West Pharmaceutical Services by 322.7% during the second quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock worth $31,000 after acquiring an additional 71 shares during the last quarter. Quarry LP grew its position in shares of West Pharmaceutical Services by 155.3% during the fourth quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock worth $34,000 after acquiring an additional 59 shares during the last quarter. Hazlett Burt & Watson Inc. acquired a new position in shares of West Pharmaceutical Services in the 1st quarter valued at $40,000. Finally, Northwest Investment Counselors LLC purchased a new stake in West Pharmaceutical Services in the 1st quarter valued at $40,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Trading Up 0.6 %

Shares of West Pharmaceutical Services stock opened at $310.92 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.68 and a current ratio of 2.34. The company has a market capitalization of $22.55 billion, a P/E ratio of 41.02, a PEG ratio of 10.58 and a beta of 1.01. West Pharmaceutical Services, Inc. has a 1 year low of $265.00 and a 1 year high of $413.70. The company’s fifty day moving average is $304.11 and its two-hundred day moving average is $337.96.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). The company had revenue of $702.10 million for the quarter, compared to analysts’ expectations of $729.36 million. West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The business’s quarterly revenue was down 6.9% compared to the same quarter last year. During the same period in the prior year, the business earned $2.11 EPS. Analysts forecast that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current year.

Insider Transactions at West Pharmaceutical Services

In related news, VP Charles Witherspoon sold 1,029 shares of the stock in a transaction on Monday, August 19th. The stock was sold at an average price of $300.00, for a total transaction of $308,700.00. Following the completion of the sale, the vice president now directly owns 1,478 shares of the company’s stock, valued at $443,400. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.